Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-29

Clinical Trial Update: A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

A 6-month extension study to assess the long-term safety of Engensis in amyotrophic lateral sclerosis has completed, with results posted on 2025-05-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Engensis (VM202)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-29